Principal Financial Group Inc. Takes $149,000 Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

Principal Financial Group Inc. bought a new position in shares of SIGA Technologies, Inc. (NASDAQ:SIGA) in the third quarter, Holdings Channel reports. The institutional investor bought 22,143 shares of the company’s stock, valued at approximately $149,000.

Several other institutional investors have also recently added to or reduced their stakes in SIGA. DekaBank Deutsche Girozentrale bought a new stake in SIGA Technologies during the second quarter worth about $40,000. China Universal Asset Management Co. Ltd. raised its position in SIGA Technologies by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,727 shares of the company’s stock valued at $93,000 after purchasing an additional 5,372 shares during the last quarter. Bayesian Capital Management LP bought a new position in SIGA Technologies in the 1st quarter valued at $97,000. AQR Capital Management LLC acquired a new position in SIGA Technologies in the second quarter worth $99,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of SIGA Technologies by 38.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,684 shares of the company’s stock worth $104,000 after purchasing an additional 3,829 shares during the last quarter. 55.40% of the stock is owned by institutional investors.

SIGA Technologies Stock Up 12.8 %

SIGA Technologies stock opened at $7.31 on Tuesday. The stock has a 50-day simple moving average of $7.02 and a 200 day simple moving average of $7.86. The stock has a market capitalization of $521.93 million, a price-to-earnings ratio of 6.09 and a beta of 0.89. SIGA Technologies, Inc. has a 12-month low of $4.26 and a 12-month high of $12.83.

SIGA Technologies (NASDAQ:SIGA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.02 earnings per share for the quarter. SIGA Technologies had a net margin of 49.33% and a return on equity of 49.06%. The firm had revenue of $10.01 million during the quarter. As a group, sell-side analysts anticipate that SIGA Technologies, Inc. will post 1.04 EPS for the current year.

SIGA Technologies Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.